Kodiak Sciences INC 8-K filings

Kodiak Sciences reported Q2 2026 results, highlighting advancements in its late-stage clinical portfolio with key data readouts anticipated in late 2026, while also noting a net loss and reduced cash reserves.

Kodiak Sciences Inc. successfully concluded its 2026 Annual Meeting of Stockholders with all director nominees elected and executive compensation approved.

Kodiak Sciences announced positive Phase 3 GLOW2 results for Zenkuda, advancing toward a multi-indication BLA submission, alongside progress in other late-stage programs and first-quarter 2026 financial results.

Kodiak Sciences announced positive Phase 3 GLOW2 study results for Zenkuda in diabetic retinopathy, alongside advancing multiple late-stage programs and reporting Q4 and full-year 2025 financial results.

Kodiak Sciences announced positive topline results from its GLOW2 Phase 3 study, demonstrating Zenkuda's superiority over sham in diabetic retinopathy treatment.

Kodiak Sciences Inc. completed a public offering of 8 million common shares, raising approximately $184 million in gross proceeds.

Kodiak Sciences Inc. reported its third-quarter 2025 financial results and highlighted significant progress across its late-stage clinical programs for retinal diseases.

Kodiak Sciences Inc. announced its second quarter 2025 financial results and provided updates on its late-stage clinical programs for retinal diseases, including tarcocimab, KSI-501, and KSI-101.

Kodiak Sciences Inc. announced that all proposals, including the election of Class I directors, advisory approval of executive compensation, and ratification of its independent auditor, were approved by stockholders at its 2025 Annual Meeting.

Kodiak Sciences reports its Q1 2025 financial results, highlighting a net loss of $57.5 million and a cash position of $138.9 million, while focusing on advancing its pipeline of Phase 3 assets targeting retinal diseases.

Kodiak Sciences reports recent business highlights, including progress in clinical trials for its retinal disease therapies, and announces its fourth quarter and full year 2024 financial results.

Kodiak Sciences announced its third quarter 2024 financial results and provided updates on its clinical programs, including the progress of tarcocimab, KSI-501, and KSI-101.

Kodiak Sciences announced its second quarter 2024 financial results and provided updates on its clinical programs, including the initiation of patient enrollment in the Phase 3 DAYBREAK study.

Kodiak Sciences held its 2024 Annual Meeting of Stockholders, electing Class III directors, approving executive compensation, and ratifying the appointment of its accounting firm.

Kodiak Sciences announced its first quarter 2024 financial results and provided updates on its clinical programs, including the advancement of tarcocimab, KSI-501, and KSI-101.

Kodiak Sciences is progressing three clinical programs towards Phase 3 value inflection points, with new studies planned for tarcocimab and KSI-501, and a Phase 1b study for KSI-101.